ArticleNeuropsychiatric disease and treatment2020
Impact of Expression and Genetic Variation of microRNA-34b/c on Cognitive Dysfunction in Patients with Major Depressive Disorder.
Article in Neuropsychiatric disease and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Association of MIR137 rs1625579 polymorphisms with cognitive function in patients with untreated first-episode depression.Acta neurologica Belgica · 2026Article
- The role of microRNAs in executive functions: a comprehensive review and bioinformatics analysis of human and animal studies.Molecular psychiatry · 2026Review
- Epigenetic Basis of Stress-Induced Central Nervous System Disorders: Therapeutic Approaches.Biology · 2026Review
- Progress in Molecular Mechanisms of Depression Induced by Mother-Infant Separation and Intervention of Traditional Chinese Medicine.Alpha psychiatry · 2025Review
- MicroRNA Expression and Neurocognitive Outcomes in Children and Young People With Primary Brain Tumor in Karachi, Pakistan: A Pilot Exploratory Study.Brain tumor research and treatment · 2025Article
- Association of MicroRNA-146a-5p Polymorphism with Cognitive Impairment in Adolescents with Depressive Disorder.Molecular syndromology · 2025Article
- Role of miRNA Gene Variants (miR-22 and miR-155) as the Factors Affecting Susceptibility to Panic Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Identification of shared gene signatures in major depressive disorder and triple-negative breast cancer.BMC psychiatry · 2024Article
- Stress, microRNAs, and stress-related psychiatric disorders: an overview.Molecular psychiatry · 2023Review
- Extracellular vesicles from cerebrospinal fluid revealed changes in miR-19a-3p and miR-4516 expression in Slovene male suicides.Genes, brain, and behavior · 2023Article
- Unlocking the enigma: unraveling multiple cognitive dysfunction linked to glymphatic impairment in early Alzheimer's disease.Frontiers in neuroscience · 2023Article
- The role of microRNAs in depression.Frontiers in pharmacology · 2023Review
- Stress-Related Exhaustion, Polygenic Cognitive Potential, and Cognitive Test Performance - A General Population Study.Cognitive therapy and research · 2023Article
- MicroRNAs as Potential Biomarkers for Exercise-Based Cancer Rehabilitation in Cancer Survivors.Life (Basel, Switzerland) · 2021Review
- MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective.Biomedicines · 2021Review
- The miRNome of Depression.International journal of molecular sciences · 2021Review
- Early-life stress induces genome-wide sex-dependent miRNA expression and correlation across limbic brain areas in rats.Epigenomics · 2021Article
- MicroRNA-dependent control of neuroplasticity in affective disorders.Translational psychiatry · 2021Review
- The important roles of microRNAs in depression: new research progress and future prospects.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Perspective on adolescent psychiatric illness and emerging role of microRNAs as biomarkers of risk.Journal of psychiatry & neuroscience : JPNArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients suffering from major depressive disorder (MDD) commonly demonstrate lower performance across multiple cognitive domains. Cognitive impairment is an intrinsic characteristic of MDD status and is often influenced by genetic factors. microRNAs (miRNAs or miRs) have been shown to have important implications in the etiology of MDD. Therefore, we aimed to identify and analyze the impact of expression and genetic variation of miR-34b/c on cognitive dysfunction in MDD.
methodsFirst, we analyzed miR-34c-5p expression in 48 cases of MDD and 54 healthy controls in a Chinese population using qRT-PCR. We assessed the relationship between the level of miR-34c-5p expression and cognitive performance by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Trail Making Test (TMT). Second, in order to characterize allelic effects of miR-34b/c on cognitive performance in MDD patients, we performed genetic association analysis of single-nucleotide polymorphism (SNP) loci of the MIR34B/C genes with cognitive function in a second group consisting of 531 MDD patients and 267 healthy controls.
resultsWe found a significant negative correlation between the level of miR-34c-5p expression and both the language and delayed memory index scores in patients with MDD. We also found a significant positive correlation between the level of miR-34c-5p expression and the time required to complete tests A and B of the TMT. The interaction between the rs2187473 genotype and the disease was significant for both immediate memory and delayed memory. In the patient group, the rs2187473 CC genotype was significantly associated with higher performance on immediate memory (
conclusionOur findings suggest that changes in miR-34c expression level have important impacts on cognitive function in patients with MDD. In particular, the polymorphism rs2187473 is a potential genetic risk factor for cognitive function in MDD, which may be of clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.